An Integrated Preclinical Platform for Comprehensive Evaluation of T-Cell Engagers

T-cell engagers (TCEs) are bispecific antibodies that simultaneously target CD3 on T cells and tumor-associated antigens, necessitating physiologically relevant models to accurately assess their mechanism of action. GemPharmatech has established an integrated preclinical platform that combines high-throughput in vitro assays for target binding, T-cell activation, and cytotoxicity with in vivo efficacy and safety studies in xenograft and syngeneic models. This platform utilizes NCG, NCG-MHC-dKO, and CD3-humanized mouse strains to enable comprehensive evaluation. Multiple TCE candidates demonstrated potent tumor growth inhibition, with efficacy closely correlated to target antigen expression and immune cell infiltration. This integrated platform provides a robust translational tool for advancing next-generation TCE in immuno-oncology.